AstraZeneca Donates $250,000 to Wilmington Boys & Girls Club for Renovation Project

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) announced a $250,000 contribution to help renovate and modernize the H. Fletcher Brown Boys & Girls Club of Wilmington as part of a campaign to improve Boys & Girls Clubs facilities across Delaware.

The AstraZeneca contribution will be used to replace security equipment and the heating, ventilating and air conditioning system at the H. Fletcher Brown Boys & Girls Club. The upgrades are included in Project Renewal, a program launched today by Delaware First Lady Carla Markell to mobilize Delaware volunteers and community to support Boys & Girls Clubs across the state.

“This is really all about Delawareans reaching out and helping each other,” said Markell. “Delaware is a state of neighbors, and neighbors help each other.”

The H. Fletcher Brown Boys & Girls Club is the first facility to go through infrastructure renovations under Project Renewal. It will be followed by volunteer efforts to paint, repair equipment and fix outdoor play areas.

The club serves more than 500 low-income school-age youth. In addition to a more energy-efficient facility, the community impact of the much needed renovations at the H. Fletcher Brown Boys and Girls Club will enable them to provide year-round health and wellness programs for youth in a safe and nurturing environment. It also will allow the club to engage more than 100 new children in the club’s many youth development and after-school programs.

“The Boys & Girls Clubs of Delaware have provided thousands of Wilmington youths with a safe place to learn, play and grow,” said Rich Fante, president, AstraZeneca U.S. and CEO North America. “Our donation is an investment in the current and future generations of Wilmington residents who need security and stability in their lives – all while having fun.”

“The H. Fletcher Brown Boys & Girls Club facility is more than 30 years old and the original equipment was antiquated, frequently broke down and not energy efficient,” said George Krupanski, president and CEO, Boys & Girls Clubs of Delaware. “Our children deserve a quality facility that they can be proud of, and this donation from AstraZeneca will greatly increase our ability to enhance services to children and families in the neighborhood.”

April 10–16 marks Delaware Week of Service, coinciding with National Volunteer Week. Volunteers throughout Delaware will lend a hand to the Boys & Girls Clubs of Delaware and other local organizations to plants gardens, paint buildings, read to children and collect food.

“It’s great that so many volunteers are contributing their time during Delaware Week of Service, and we hope that they will continue to do so throughout the year since the needs are so great,” said Martha Carper, chair of the Boys & Girls Club board.

About Boys & Girls Clubs of Delaware

The Boys & Girls Clubs of Delaware is the largest provider of before and after school programs in the state of Delaware, providing positive, quality programming to more than 25,000 youth annually at 44 sites across the state. The Boys & Girls Clubs of Delaware provides an unparalleled experience implementing programs for all youth, particularly those who need us the most. The mission is to enable all young people to reach their full potential as productive, caring and responsible citizens. For more information, visit www.bgclubs.org.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).



CONTACT:

Media Inquiries:
AstraZeneca
Lynn Shepherd, 302-885-8911
or
AstraZeneca U.S. Media Line:
302-885-2677

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Philanthropy  Children  Other Philanthropy  Consumer

MEDIA:

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.